GSK and Moderna settle patent dispute over COVID and RSV vaccines

GSK (GSK) and Moderna (MRNA) have settled lawsuits alleging that Moderna’s COVID-19 vaccines Spikevax and mNEXSPIKE, and its RSV shot mResvia, infringed the British drugmaker’s patents.
Moderna said it settled GSK’s patent litigation in the US and Europe on October 28, and that the companies had granted each other patent cross-licenses in the field of infectious disease. Neither is obliged to make payments of any kind in connection with the licenses. A GSK spokesperson said the company was pleased to have reached a resolution that provided clarity for both groups and allowed continued focus on advancing innovation for patients.
The companies have asked a Delaware federal court to dismiss GSK’s US infringement claims with prejudice, meaning they cannot be refiled.
GSK sued Moderna in 2024 over the lipid nanoparticle technology used in the vaccines to carry fragile messenger RNA into the body. It filed a similar suit against Pfizer (PFE) and BioNTech (BNTX) over their COVID-19 vaccine earlier that year, which is still ongoing.
The cases form part of a web of US litigation involving Pfizer, BioNTech and Moderna over patent royalties on technology used in their COVID vaccines, including a suit Moderna brought against Pfizer in 2022.